Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Childhood Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Childhood Neoplasm

Cancer Family

Childhood Neoplasm

CI-CAN-00000009Explore in graph →

PediatricNon-malignant312 active trials1 approved drugs68 evidence items

NCIt: C6283

Overview
Statistics
Survival
Genomics1
Variants & evidence68
Drugs16
Trials1503
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (43)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–43 of 43 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
· J Clin Oncol · 2010 · PMID 20713864 · validated civic_curation pubmed
Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.
· Pediatr Blood Cancer · 2018 · PMID 29893456 · validated civic_curation pubmed
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
· J Transl Med · 2014 · PMID 25524464 · validated civic_curation pubmed
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.
· J Med Genet · 2010 · PMID 20543203 · validated civic_curation pubmed
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
· Cancer · 2018 · PMID 30204247 · validated civic_curation pubmed
Refractory and metastatic infantile fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable response to crizotinib.
· Cold Spring Harb Mol Case Stud · 2019 · PMID 30709876 · validated civic_curation pubmed
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
· Mod Pathol · 2018 · PMID 29099503 · validated

Showing 26–43 of 43 publications

← Previous
1
2
Next →

civic_curation

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.

· Ann Oncol · 2019 · PMID 32223937 · validated civic_curation pubmed

Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma.

· Cold Spring Harb Mol Case Stud · 2015 · PMID 27148571 · validated civic_curation pubmed

Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.

· Pediatr Blood Cancer · 2016 · PMID 27093299 · validated civic_curation pubmed

Immunophenotype-Genotype Correlations in Clear Cell Sarcoma of Kidney-An Evaluation of Diagnostic Ancillary Studies.

· Pediatr Dev Pathol · 2020 · PMID 32364435 · validated civic_curation pubmed

Mutually exclusive BCOR internal tandem duplications and YWHAE-NUTM2 fusions in clear cell sarcoma of kidney: not the full story.

· J Pathol · 2016 · PMID 27000436 · validated civic_curation pubmed

Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion.

· Histopathology · 2018 · PMID 28833375 · validated civic_curation pubmed

BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney.

· Pediatr Blood Cancer · 2020 · PMID 31876361 · validated civic_curation pubmed

Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues.

· Am J Surg Pathol · 2017 · PMID 28817404 · validated civic_curation pubmed

Supratentorial ependymoma with YAP1:FAM118B fusion: A case report.

· Neuropathology · 2021 · PMID 33480048 · validated civic_curation pubmed

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

· Oncotarget · 2017 · PMID 28002790 · validated civic_curation pubmed

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.

· Oncotarget · 2017 · PMID 29156677 · validated civic_curation pubmed